Glaucoma Risk Factors and Outcomes Following Boston Keratoprosthesis Type 1 Surgery

被引:18
|
作者
Geoffrion, Dominique [1 ,2 ]
Harissi-Dagher, Mona [2 ]
机构
[1] McGill Univ, Fac Med, Dept Expt Surg, Montreal, PQ, Canada
[2] Ctr Hosp Univ Montreal CHUM, Dept Ophthalmol, 1051 Sanguinet,D-01-2273, Montreal, PQ H2X 3E4, Canada
关键词
VISUAL OUTCOMES; COMPLICATIONS; PROGRESSION; MANAGEMENT; VISION; EYES;
D O I
10.1016/j.ajo.2021.01.006
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To evaluate glaucoma risk factors and associated outcomes of the Boston keratoprosthesis type I (KPro). DESIGN: Clinical case-control study. METHODS: This is a single-center study of 140 eyes of 118 patients who underwent KPro surgery between October 2008 and March 2017 by a single surgeon. A total of 118 eyes of 118 patients with at least 6 months of follow-up were analyzed to account for intereye correlation. Patients without glaucoma were compared to those diagnosed with glaucoma, which included treatment with intraocular pressure (IOP)-lowering medications or glaucoma surgery. A subgroup analysis compared eyes with pre-KPro glaucoma with those with post-KPro glaucoma. Statistical analysis was performed using univariate and multivariate analyses and Kaplan-Meier survival curves. Main outcome measures were glaucoma diagnosis and progression. Other outcomes included demographics, preoperative diagnosis, best-corrected visual acuity, IOP, cup-to-disc ratio progression and postoperative complications. RESULTS: The mean age at surgery was 60.7 +/- 16.7 years, with a follow-up of 6.9 +/- 3.2 years. De novo KPro glaucoma incidence was 24% (n = 28/118), equivalent to 3.4 cases per 100 eye-years, with onset at 2.1 +/- 2.2 postoperative years. A total of 17 of 118 eyes (14%) did not have glaucoma. Multiple logistic regression showed that high preoperative IOP was a predictor of higher rates of glaucoma development (odds ratio [OR] = 1.538, 95% confidence interval [CI] = 1.030-2.297, P = .035) and progression (OR = 1.450, 95% CI = 1.084-1.937, P = .012). Stromal and endothelial disorders were protective preoperative diagnoses for glaucoma progression after KPro (OR = 0.002, 95% CI = 0.000-0.227, P = .010). A greater proportion of eyes with autoimmune and ocular surface diseases developed de novo glaucoma after KPro compared with other preoperative diagnoses (P < .05). A total of 45% of glaucomatous KPro eyes suffered postoperative glaucoma progression. The mean final best corrected visual acuity of the cohort was 1.76 +/- 1.0, with no difference between eyes with and without glaucoma (P > .05). The rate of serious vision-threatening complications was higher in KPro eyes without glaucoma (77%) than in those with glaucoma (41%, P = .006). CONCLUSIONS: High preoperative IOP signals a higher risk for glaucoma development and progression after KPro surgery. Autoimmune diseases and ocular surface diseases precipitate de novo glaucoma, whereas stromal and endothelial disorders protect against glaucoma progression after KPro. The minority of KPro eyes without glaucoma remain at high risk of complications that can hinder promising visual outcomes. Despite all available treatments and surgical interventions, a majority of eyes will suffer from glaucoma progression, even later during follow-up. ((C) 2021 Elsevier Inc. All rights reserved.)
引用
收藏
页码:56 / 67
页数:12
相关论文
共 50 条
  • [41] Safety of Concurrent Boston Type I Keratoprosthesis and Glaucoma Drainage Device Implantation
    Lenis, Tamara L.
    Chiu, Stephan Y.
    Law, Simon K.
    Yu, Fei
    Aldave, Anthony J.
    OPHTHALMOLOGY, 2017, 124 (01) : 12 - 19
  • [42] Outcomes of Boston keratoprosthesis type 1 reimplantation: multicentre study results
    Wang, Jay C.
    Rudnisky, Christopher J.
    Belin, Michael W.
    Ciolino, Joseph B.
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2018, 53 (03): : 284 - 290
  • [43] Outcomes of Boston Keratoprosthesis Type I Implantation in Poland: A Retrospective Study on 118 Patients
    Wroblewska-Czajka, Ewa
    Dobrowolski, Dariusz
    Wylegala, Adam
    Jurkunas, Ula V.
    Wylegala, Edward
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (04)
  • [44] Wide-field vitreoretinal surgery in eyes with Boston type 1 keratoprosthesis
    Utine, Canan Asli
    Kaya, Mahmut
    Kasal, Kivanc
    INTERNATIONAL OPHTHALMOLOGY, 2022, 42 (03) : 997 - 1005
  • [45] Endoscopic Cyclophotocoagulation for the Treatment of Glaucoma in Boston Keratoprosthesis Type II Patient
    Poon, Linda Yi-Chieh
    Chodosh, James
    Vavvas, Demetrios G.
    Dohlman, Claes H.
    Chen, Teresa C.
    JOURNAL OF GLAUCOMA, 2017, 26 (04) : E146 - E149
  • [46] Systematic Review and Meta-Analysis of the Medium- and Long-Term Outcomes of the Boston Type 1 Keratoprosthesis
    Priddy, Jack
    Bardan, Ahmed Shalaby
    Tawfik, Hadeel Sherif
    Liu, Christopher
    CORNEA, 2019, 38 (11) : 1465 - 1473
  • [47] Boston Keratoprosthesis Type 1 in Chemical Burns
    Salvador-Culla, Borja
    Kolovou, Paraskevi E.
    Arzeno, Linnette
    Martinez, Santiago
    Lopez, Miguel A.
    CORNEA, 2016, 35 (06) : 911 - 916
  • [48] Retroprosthetic Membrane Formation in Boston Keratoprosthesis Type 1: Incidence, Predisposing Factors, Complications, and Treatment
    Khair, Diana
    Daoud, Roy
    Harissi-Dagher, Mona
    CORNEA, 2022, 41 (06) : 751 - 756
  • [49] Boston Type 1 Keratoprosthesis: Updated Perspectives
    Nonpassopon, Manachai
    Niparugs, Muanploy
    Cortina, Maria Soledad
    CLINICAL OPHTHALMOLOGY, 2020, 14 : 1189 - 1200
  • [50] Boston type 1 keratoprosthesis: the CHUM experience
    Robert, Marie-Claude
    Harissi-Dagher, Mona
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2011, 46 (02): : 164 - 168